Get started

REGN

NVAX STOCKS DUMPED, DOWNTREND CONTINUESEarlier this year there was the question : How do you invest in Coronavirus vaccine stocks? Now, we have the answer : YOU DONT. Chart looking bleak, and the support lines are weak. This could be due to a few reasons: - Lack of MAINSTREAM updates - NVAX actually has no other vaccines - Market volatility due to covid and elections - Investors are seeking less riskier gains and getting out of stocks that do not look promising Other than the above, we have seen strange behavior with stocks of companies in the race. A few examples: PFE Pfizer stock not responding to numerous huge injections from government REGN Regeneron stocks hardly responding to Trump pimp GILD Gilead even FALLING after being the first company world wide to receive FDA approval for remdesivir as a treatment. AZN Astrazeneca in conjunction with Oxford has a trail candidate dead but stocks remain largely unaffected I think NVAX has potential in the long run, long term I remain bullish for the company fundamentally, but not for an investment choice right now. In fact I'd say that no vaccine stock is a good investment right now. The way the market reacts to news is too unpredictable and the future remains uncertain. Hit like if you found this insightful and helpful Thanks, Ev
NASDAQ:NVAX
by BlockTechEv
1
Gild Bullish trend-line PlayGilead Sciences , Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. Entry $77.50 area Target $2 trailing stoploss I been trading this stock for over a year now and once it form it's base, it usually hold itself very well in it's pattern. we could've easily scalped this stock multiple time this month for easy gain if you just buy the dip at the trend line with a tight stoploss.
NASDAQ:GILDLong
by WallSt007
XBI Potential What is XBi? XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with relatively small pharma overlap as we see it. This highly efficient fund, which charges less than competing funds, has a history of beating its index due to revenue from securities lending. It has attracted a large asset base and trades with excellent volume. The fund’s alternative take on the space earns it a place on our Opportunities List. Looking like we could see a pull back here or breakout. Risk and reward is in our favor here. if it rejects, it can go to $95 area, if it breaks out, we can just stoploss for $1.
AMEX:XBI
by WallSt007
2